The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace

An experimental treatment to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial, Shire PLC announced this morning. Source: BioSpace

Roche's patent dispute with Shire over the new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some…

Cue BioPharma is on a roll, having recently signed a deal with Merck and is planning an IPO to raise up to $60M. Source: BioSpace

Together, Boehringer Ingelheim and Roche will leverage complementary expertise and innovative LNA technology to bring novel treatment approaches to IBD patients. Source: BioSpace

A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal. Source: BioSpace

Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018. Source: BioSpace

The five top-selling drugs brought in a combined $48B so far this year. Source: BioSpace

Chiome Bioscience says it announces termination of candidate antibody related joint research contract, which was signed between the co and Chugai Pharma, as the contract has expired on Dec. 31…

The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions. Source: BioSpace